Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram–Negative Organisms?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Microbial Drug Resistance

• Publication date

  2017-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/mdr.2016.0043PMID 27564414
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tigecycline

  2018cited by this paper
• Predictors of Mortality in Blood Stream Infections caused by Extended Spectrum Beta Lactamase Producing Enterobacteriaceae

  2017cited by this paper
• Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial

  2016cited by this paper
• Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections

  2016cited by this paper
• Protective effects of minocycline on experimental spinal cord injury in rats.

  2015cited by this paper
• Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

  2015cited by this paper
• Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature.

  2015cited by this paper
• Tetracyclines for multidrug-resistant Acinetobacter baumannii infections.

  2015cited by this paper
• Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

  2015cited by this paper
• Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs.

  2015cited by this paper
• Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013

  2015influential reference
• Successful use of tigecycline for treatment of culture-negative pyogenic vertebral osteomyelitis

  2015cited by this paper
• Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations

  2015cited by this paper
• Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.

  2015cited by this paper
• Interventions for rosacea: abridged updated Cochrane systematic review including GRADE assessments

  2015cited by this paper
• Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center.

  2014cited by this paper
• Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.

  2014cited by this paper
• Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis.

  2014cited by this paper
• Cerebrospinal fluid penetration of tigecycline

  2014cited by this paper
• Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance.

  2014cited by this paper
• Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections

  2014cited by this paper
• Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients

  2014cited by this paper
• High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria

  2014cited by this paper
• Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.

  2014cited by this paper
• Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis

  2014cited by this paper
• Post Neurosurgical Meningitis due to Colistin Heteroresistant Acinetobacter baumannii

  2014cited by this paper
• Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii?

  2014cited by this paper
• Carbapenem-Resistant Klebsiella pneumoniae Urinary Tract Infection following Solid Organ Transplantation

  2014cited by this paper
• Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections.

  2014cited by this paper
• Tigecycline for severe Clostridium difficile infection.

  2014cited by this paper
• Multidrug-resistant tet(X)-containing hospital isolates in Sierra Leone.

  2013cited by this paper
• Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia

  2013cited by this paper
• The emergence of clinical resistance to tigecycline.

  2013cited by this paper
• Tigecycline: an update.

  2013cited by this paper
• Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.

  2012cited by this paper
• Excess deaths associated with tigecycline after approval based on noninferiority trials.

  2012cited by this paper
• Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.

  2012cited by this paper
• Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection

  2012cited by this paper
• Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin

  2012cited by this paper
• Minocycline: A Review of its Antibacterial and Pharmacokinetic Properties and Therapeutic Use

  2012cited by this paper
• Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: A case report and review of the literature

  2012cited by this paper
• Minocycline Hydrochloride: The Emerging Evidence of Its Therapeutic Value in Complicated Bacterial Infections

  2011cited by this paper
• Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.

  2011cited by this paper
• Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.

  2011cited by this paper
• Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysis.

  2011cited by this paper
• Efficacy and safety of tigecycline: a systematic review and meta-analysis.

  2011cited by this paper
• Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline

  2011cited by this paper
• Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysis.

  2011cited by this paper
• Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients

  2011cited by this paper
• Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia

  2010cited by this paper
• Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

  2010cited by this paper
• Oral biofilms: a reservoir of transferable, bacterial, antimicrobial resistance

  2010cited by this paper
• Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease

  2010cited by this paper
• Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.

  2010cited by this paper
• Cerebral Spinal Fluid Penetration of Tigecycline in a Patient with Acinetobacter baumannii Cerebritis

  2010cited by this paper
• Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem.

  2009cited by this paper
• Pharmacokinetic Considerations regarding Tigecycline for Multidrug-Resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii Urosepsis

  2009cited by this paper
• Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii.

  2009cited by this paper
• Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline.

  2009cited by this paper
• Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.

  2009cited by this paper
• Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline.

  2009cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline

  2009cited by this paper
• Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.

  2009cited by this paper
• Detection of Plasmid-Mediated KPC-Producing Klebsiella pneumoniae in Ottawa, Canada: Evidence of Intrahospital Transmission

  2009cited by this paper
• Establishing the role of tigecycline in an era of antimicrobial resistance

  2008cited by this paper
• Minocycline Therapy for Traumatic Wound Infections Caused by the Multidrug-Resistant Acinetobacter baumannii-Acinetobacter calcoaceticus Complex

  2008cited by this paper
• Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

  2008cited by this paper
• A review of tigecycline--the first glycylcycline.

  2008cited by this paper
• Absence of an Interaction Between Tigecycline and Digoxin in Healthy Men

  2007cited by this paper
• Tigecycline for Treatment of Pneumonia and Empyema Caused by Carbapenemase‐Producing Klebsiella pneumoniae

  2007cited by this paper
• Early Experience with Tigecycline for Ventilator‐Associated Pneumonia and Bacteremia Caused by Multidrug‐Resistant Acinetobacter baumannii

  2007cited by this paper
• Tigecycline: a critical analysis.

  2006cited by this paper
• Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.

  2006cited by this paper
• The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

  2005cited by this paper
• Tigecycline

  2005cited by this paper
• The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

  2005cited by this paper
• Tigecycline.

  2005cited by this paper
• Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

  2005cited by this paper
• Antibacterial prescribing and warfarin: a review

  2003cited by this paper
• Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia

  2003influential reference
• Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance

  2001influential reference
• Glycylcyclines: third-generation tetracycline antibiotics.

  2001cited by this paper
• The use of tetracyclines for the treatment of sarcoidosis.

  2001cited by this paper
• Benefits and Risks of Minocycline in Rheumatoid Arthritis

  2000cited by this paper
• Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution.

  1996cited by this paper
• Gene cassettes: a new class of mobile element.

  1995cited by this paper
• Epidemiology of tetracycline-resistance determinants.

  1994cited by this paper
• Minocycline: old and new therapeutic uses.

  1994cited by this paper
• Penetration of minocycline into lung tissues.

  1991cited by this paper
• Characterization of the Tet M determinants in urogenital and respiratory bacteria

  1990cited by this paper
• Plasmid-mediated Tet M in Haemophilus ducreyi

  1989cited by this paper
• Frequency of tetracycline resistance determinant classes among lactose-fermenting coliforms

  1983cited by this paper
• Heterogeneity of tetracycline resistance determinants.

  1980cited by this paper
• Side Effects of Minocycline: Different Dosage Regimens

  1977cited by this paper

• Combating Klebsiella pneumoniae: from antimicrobial resistance mechanisms to phage-based combination therapies

  2025cites this paper
• Analysis of Bacterial Coinfections in Patients with Mild, Moderate, and Severe COVID-19

  2025cites this paper
• Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin

  2023cites this paper
• Drug repurposing through virtual screening and in vitro validation identifies tigecycline as a novel putative HCV polymerase inhibitor.

  2022cites this paper
• Tetracyclines and bone: Unclear actions with potentially lasting effects.

  2022cites this paper
• Infections Due to Acinetobacter baumannii-calcoaceticus Complex: Escalation of Antimicrobial Resistance and Evolving Treatment Options.

  2022cites this paper
• In vitro evaluation of antibiotic synergy for carbapenem-resistant Klebsiella pneumoniae clinical isolates

  2021cites this paper
• In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from skin and soft tissue infections

  2021cites this paper
• Bacterial Antibiotic Resistance: The Most Critical Pathogens

  2021cites this paper
• Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review

  2021cites this paper
• A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections

  2021cites this paper
• Impact of oxytetracycline on anaerobic wastewater treatment and mitigation using enhanced hydrolysis pretreatment.

  2020cites this paper
• Minocycline, Focused on mechanisms of resistance, antibacterial activity, and clinical effectiveness; Back to Future.

  2020cites this paper
• A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary

  2020cites this paper
• Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies

  2020cites this paper
• Alternative drugs against multiresistant Gram-negative bacteria.

  2020cites this paper
• Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems

  2020cites this paper
• Layered biocompatible pH-responsive antibacterial composite film based on HNT/PLGA/chitosan for controlled release of minocycline as burn wound dressing.

  2020cites this paper
• Minimum inhibitory concentrations and resistance for selected antimicrobial agents (including imipenem, linezolid and tigecycline) of bacteria obtained from eye infections

  2020cites this paper
• Epidemiological and genomic characteristics of Acinetobacter baumannii from different infection sites using comparative genomics

  2020cites this paper
• Tigecycline: Role in the Management of cIAI and cSSTI in the Indian Context

  2020cites this paper
• Omadacycline - The Newest Tetracycline.

  2019cites this paper
• Molecular Epidemiology of Multidrug-Resistant Klebsiella pneumoniae Isolates in a Brazilian Tertiary Hospital

  2019cites this paper
• In-vitro activity of tigecycline and comparator agents against common pathogens: Indian experience.

  2019cites this paper
• Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from In vitro study

  2019cites this paper
• Colistin-sparing approaches with newer antimicrobials to treat carbapenem-resistant organisms: Current evidence and future prospects

  2019cites this paper
• Bad bug, no test: Tigecycline susceptibility testing challenges and way forward

  2019cites this paper
• Surprising synergy of dual translation inhibition vs. Acinetobacter baumannii and other multidrug-resistant bacterial pathogens

  2019cites this paper
• Developmental dynamics of antibiotic resistome in aerobic biofilm microbiota treating wastewater under stepwise increasing tigecycline concentrations.

  2019cites this paper
• In vitro assessment of cefoperazone-sulbactam based combination therapy for multidrug-resistant Acinetobacter baumannii isolates in China.

  2018cites this paper
• Susceptibility of Minocycline against Carbapenem Resistant Gram-Negative Bacilli

  2018cites this paper
• Can minocycline be a carbapenem sparing antibiotic? Current evidence

  2016cites this paper